Search research articles
Contact Us
Filters
Showing results (71-80 of 161) with videos related to
Page
of 17
Sort By:
Cancer Immunology, Immunotherapy : CII
|
June 30, 2022
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome
Sandra van Wilpe, Shabaz Sultan, Mark A J Gorris, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 8, 2021
[<sup>68</sup>Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [<sup>177</sup>Lu]Lu-PSMA-617 treatment
Steffie M B Peters, Regina Hofferber, Bastiaan M Privé, et al.
European Urology Focus
|
July 30, 2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey
David Lorente, Praful Ravi, Niven Mehra, et al.
European Urology Oncology
|
April 29, 2025
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis
Debbie G J Robbrecht, Youssra Salhi, John W M Martens, et al.
European Urology Oncology
|
October 9, 2024
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial
Noel W Clarke, Andrew J Armstrong, Mototsugu Oya, et al.
JCO Precision Oncology
|
December 7, 2023
Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer
Anouk C de Jong, Khrystany T Isebia, Sui Wai Ling, et al.
Clinical Genitourinary Cancer
|
May 10, 2023
Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC
Babette I Laarhuis, Marcel J R Janssen, Michiel Simons, et al.
Molecular Oncology
|
March 2, 2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment
Emmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
European Urology Oncology
|
March 14, 2024
A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer
Emmy Boerrigter, Joanneke K Overbeek, Guillemette E Benoist, et al.
The Lancet. Oncology
|
August 1, 2024
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
Catharina J P Op 't Hoog, Niven Mehra, Marc Maliepaard, et al.
Page
of 17
Search research articles
Search
Showing results (71-80 of 161) with videos related to
Sort By:
Page
of 17
Cancer Immunology, Immunotherapy : CII
|
June 30, 2022
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome
Sandra van Wilpe, Shabaz Sultan, Mark A J Gorris, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 8, 2021
[<sup>68</sup>Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [<sup>177</sup>Lu]Lu-PSMA-617 treatment
Steffie M B Peters, Regina Hofferber, Bastiaan M Privé, et al.
European Urology Focus
|
July 30, 2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey
David Lorente, Praful Ravi, Niven Mehra, et al.
European Urology Oncology
|
April 29, 2025
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis
Debbie G J Robbrecht, Youssra Salhi, John W M Martens, et al.
European Urology Oncology
|
October 9, 2024
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial
Noel W Clarke, Andrew J Armstrong, Mototsugu Oya, et al.
JCO Precision Oncology
|
December 7, 2023
Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer
Anouk C de Jong, Khrystany T Isebia, Sui Wai Ling, et al.
Clinical Genitourinary Cancer
|
May 10, 2023
Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC
Babette I Laarhuis, Marcel J R Janssen, Michiel Simons, et al.
Molecular Oncology
|
March 2, 2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment
Emmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
European Urology Oncology
|
March 14, 2024
A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer
Emmy Boerrigter, Joanneke K Overbeek, Guillemette E Benoist, et al.
The Lancet. Oncology
|
August 1, 2024
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
Catharina J P Op 't Hoog, Niven Mehra, Marc Maliepaard, et al.
Page
of 17